Ponatinib (AP24534) hydrochloride is a hydrochloride of ponatinib. Ponatinib is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively
*The following content is generated by AI and is for reference only.
Overview
Ponatinib hydrochloride is a third-generation tumor-selective tyrosine kinase inhibitor. Synthesized via multi-step organic coupling, it targets BCR-ABL with high potency. Molecular Formula: C26H21F4N5O·HCl; CAS No.: 950736-82-0.
Application
- Oncology Manufacturing: Production of oral tablets for chronic myeloid leukemia (CML).
- Pharmaceutical R&D: Active Pharmaceutical Ingredient (API) for clinical trials targeting T315I mutations.
- Diagnostics: Reference standard for bioanalytical method validation in pharmacokinetic studies.
Precautions
Strictly contraindicated for patients with severe arterial occlusive events. Store under controlled temperature (2-8°C) in desiccated conditions. Personnel must utilize respiratory protection and nitrile gloves during handling to prevent dermal exposure.